Law Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of Chelsea Therapeutics International, Ltd. Stockholders
08 Mayo 2014 - 5:35PM
Business Wire
Kirby McInerney LLP is investigating potential claims against
the Board of Directors of Chelsea Therapeutics International, Ltd.
(“Chelsea Therapeutics” or the “Company”) (NASDAQ: CHTP) concerning
the proposed acquisition of the Company by H. Lundbeck A/S
(“Lundbeck”). Under the terms of the definitive merger agreement,
Chelsea Therapeutics stockholders will receive $6.44 in cash and up
to $1.50 in Contingent Value Rights for each share of Chelsea
Therapeutics owned, representing a total potential consideration of
up to $658 million.
The investigation concerns whether the Chelsea Therapeutics
Board of Directors violated its fiduciary duties by agreeing to the
proposed transaction and whether the proposed consideration
adequately values Chelsea Therapeutics’ common stock.
If you are a Chelsea Therapeutics stockholder and wish to obtain
additional information, please contact J. Brandon Walker, Esq.
by email at bwalker@kmllp.com, by telephone at (212) 699-1145 or
(888) 529-4787, or by filling out this contact form. There is no
cost or obligation to you.
Kirby McInerney LLP is a New York-based law firm concentrating
in securities, shareholder, whistleblower, antitrust and consumer
litigation. For additional information, please go to
www.kmllp.com.
Kirby McInerney LLPJ. Brandon Walker, Esq.212-699-1145 /
888-529-4787bwalker@kmllp.com
Chelsea Therapeutics International, Ltd. (MM) (NASDAQ:CHTP)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Chelsea Therapeutics International, Ltd. (MM) (NASDAQ:CHTP)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Chelsea Therapeutics International, Ltd. (MM) (NASDAQ): 0 recent articles
Más de Chelsea Therapeutics International, Ltd. (MM) Artículos de Noticias